AKABY
Price:
$90
Market Cap:
$59.92B
ALK-Abelló A/S operates as a global leader in allergy solutions, serving markets across Europe, North America, and internationally. The company provides a diverse range of allergy immunotherapy (AIT) products, offered as injections, sublingual drops, and tablets, specifically formulated to address common allergies like house dust mite, grass, tree pollen, ragweed, and Japanese cedar. In addition to these therapeutic options, ALK-Abelló manufactures adrenaline auto-injectors for emergency treatment of severe allergic reactions and produces diagnostic tools for allergy identification. Prominent products for allergic rhinitis include GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and...[Read more]
Industry
Biotechnology
IPO Date
2013-09-05
Stock Exchange
OTC
Ticker
AKABY
According to ALK-Abelló A/S’s latest financial reports and current stock price. The company's current PE Ratio is 3.00K. This represents a change of 7.93% compared to the average of 37.35 of the last 4 quarters.
The mean historical PE Ratio of ALK-Abelló A/S over the last ten years is 102.39. The current 3.00K PE Ratio has changed 292.91% with respect to the historical average. Over the past ten years (40 quarters), AKABY's PE Ratio was at its highest in in the March 2017 quarter at 1.24K. The PE Ratio was at its lowest in in the June 2017 quarter at -2389.25.
Average
102.39
Median
42.76
Minimum
-356.45
Maximum
1.09K
Discovering the peaks and valleys of ALK-Abelló A/S PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 453.21%
Maximum Annual PE Ratio = 1.09K
Minimum Annual Increase = -406.25%
Minimum Annual PE Ratio = -356.45
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | 42.31 | -2.08% |
| 2024 | 43.20 | -6.18% |
| 2023 | 46.05 | -27.16% |
| 2022 | 63.22 | -63.20% |
| 2021 | 171.81 | -84.26% |
| 2020 | 1.09K | -406.25% |
| 2019 | -356.45 | 453.21% |
| 2018 | -64.43 | 37.36% |
| 2017 | -46.91 | -240.23% |
| 2016 | 33.45 | 35.35% |
The current PE Ratio of ALK-Abelló A/S (AKABY) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
43.85
5-year avg
73.32
10-year avg
102.39
ALK-Abelló A/S’s PE Ratio is greater than Abcam plc (578.45), greater than IVERIC bio, Inc. (-27.51), greater than Global Blood Therapeutics, Inc. (-14.22), greater than Alpine Immune Sciences, Inc. (-100.94), greater than Arena Pharmaceuticals, Inc. (-8.82), greater than Mirati Therapeutics, Inc. (-4.46), greater than Reata Pharmaceuticals, Inc. (-20.07), greater than Churchill Capital Corp XI (1.23K), greater than Turning Point Therapeutics, Inc. (-13.03), greater than RayzeBio, Inc. Common Stock (-35.73),
| Company | PE Ratio | Market cap |
|---|---|---|
| 578.45 | $5.12B | |
| -27.51 | $5.51B | |
| -14.22 | $0 | |
| -100.94 | $4.46B | |
| -8.82 | $0 | |
| -4.46 | $4.12B | |
| -20.07 | $6.57B | |
| 1.23K | $428.22M | |
| -13.03 | $0 | |
| -35.73 | $3.75B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ALK-Abelló A/S using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ALK-Abelló A/S or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is ALK-Abelló A/S's PE Ratio?
How is the PE Ratio calculated for ALK-Abelló A/S (AKABY)?
What is the highest PE Ratio for ALK-Abelló A/S (AKABY)?
What is the 3-year average PE Ratio for ALK-Abelló A/S (AKABY)?
What is the 5-year average PE Ratio for ALK-Abelló A/S (AKABY)?
How does the current PE Ratio for ALK-Abelló A/S (AKABY) compare to its historical average?